It’s been a busy year for everyone and it’s almost over. We at InVitria wanted to take a moment to recap some of the white papers, webinars, and other publications that you may have missed.
Revolutionizing T Cell Immunotherapies
Eliminate Serum & Blood-Derived Components from Your Immunotherapy Applications
Better Quality and Performance Starts with Better Proteins and Components
Click to learn more about how InVitria is improving the manufacturing of biopharmaceuticals with serum-free recombinant components.
Poster
Exbumin Provides Improved Performance and Stability in Vaccine Development
InVitria Serum Free Cell Culture Media Components & Optimization
Product Applications
InVitria’s portfolio of chemically defined blood-free products enables development and production of novel therapeutics without use of any blood-derived components.
Click on the application of interest to find out how our products set the new standards in biologics manufacturing.
Product Types
InVitria offers a suite of recombinant protein products, each of which is completely free of animal or human components and produced in a scalable, non-mammalian recombinant expression system at an ISO9001:2015 certified facility in Kansas, USA.
Custom Media Formulation
InVitria is the leading brand of custom media formulations for gene therapy, cell therapy, vaccine & antibody production, and related culturing applications. Contact us to discuss your cell culture needs. Let us do the heavy lifting!
- Blood-Free & Chemically Defined
- High Performance
- Reliable Supply Chain
- Faster Time to Market
2021 Product Catalog
Download InVitria’s Product Catalog to learn more about our:
- Recombinant Proteins
- Cell Culture Supplements
- Blood-Free Cell Culture Media
Search Our Knowledge Base
Select the cell line or an application of interest and discover more information relevant to your work.
Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times
- Decreased variability in cell culture media.
- Accelerated gene therapy research.
- Improved scalability & increased speed of gene therapy manufacturing.
- Reduced cost in time and resources for manufacturing.